{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"72.4","value":"3.1"},{"groupId":"OG001","spread":"126.4","value":"2.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"486"},{"groupId":"OG001","value":"487"}],"units":"Participants"}],"title":"Day 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"413.1","value":"27.4"},{"groupId":"OG001","spread":"48.3","value":"2.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"404"},{"groupId":"OG001","value":"403"}],"units":"Participants"}],"title":"Day 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"38.4","value":"-5.6"},{"groupId":"OG001","spread":"42.3","value":"-4.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"265"},{"groupId":"OG001","value":"282"}],"units":"Participants"}],"title":"Day 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"46.4","value":"-10.6"},{"groupId":"OG001","spread":"208.3","value":"6.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"200"}],"units":"Participants"}],"title":"Day 11"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"110.1","value":"-6.0"},{"groupId":"OG001","spread":"91.0","value":"-3.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"246"},{"groupId":"OG001","value":"266"}],"units":"Participants"}],"title":"Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"46.7","value":"-17.1"},{"groupId":"OG001","spread":"291.1","value":"2.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"251"},{"groupId":"OG001","value":"251"}],"units":"Participants"}],"title":"Day 29"}],"denoms":[{"counts":[{"groupId":"OG000","value":"486"},{"groupId":"OG001","value":"487"}],"units":"Participants"}],"description":"Blood to evaluate AST was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.","dispersionType":"Standard Deviation","groups":[{"description":"200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib administered orally daily for the duration of the hospitalization up to a 14-day total course.","id":"OG000","title":"Remdesivir Plus Baricitinib"},{"description":"200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib Placebo administered orally daily for the duration of the hospitalization up to a 14-day total course.","id":"OG001","title":"Remdesivir Plus Placebo"}],"paramType":"MEAN","populationDescription":"The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.","reportingStatus":"POSTED","timeFrame":"Days 1, 3, 5, 8, 11, 15 and 29","title":"Change From Baseline in Aspartate Transaminase (AST)","type":"SECONDARY","unitOfMeasure":"Units/Liter (U/L)"}